The US FDA has granted approval to Vabysmo (faricimab) 6mg single-dose prefilled syringe (PFS) for treating neovascular or ‘wet’ age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). US availability is anticipated in the upcoming months
Vabysmo’s approval was based on studies showing improved visions and retinal drying in nAMD, DME and RVO. Other worldwide health authority reviews are underway
Vabysmo, the first bispecific antibody for the eye, targets and inhibits Ang-2 and VEGF-A, pathways linked to vision loss due to destabilization of blood vessels that results in leaky vessels & increased inflammation
Ref: Roche | Image: Roche
Related News:- Roche Reports the CHMP’s Positive Opinion of Vabysmo for Retinal Vein Occlusion (RVO)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
